Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04219254 · ClinicalTrials.gov registry record · Phase 1

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1 study of Solid Tumor, Adult, sponsored by BioInvent International AB.

Recruiting
Registry status
Phase 1
Development phase
197
Enrollment target
20
Study locations

NCT04219254 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by BioInvent International AB. The registered enrollment target is 197 participants, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04219254, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by BioInvent International AB.

RECRUITING
Registry status
Phase 1
Development phase
197 participants
Enrollment target
20
Study locations

Study Summary

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG BI1206

Study Locations (20)

Other

  • LTD High Technology Hospital Med Center - Batumi
  • Israel-Georgian Medical Research Clinic Helsicore - Tbilisi
  • Jerarsi Clinic - Tbilisi
  • Medizinische Hochschule Hannover - Hanover
  • Nationales Centrum für Tumorerkrankungen - Heidelberg
  • Universität des Saarlandes - Homburg
  • Maria Skłodowska-Curie National Institute of Oncology - Gliwice
  • Medical University of Silesia - Katowice
  • Instytut Centrum Zdrowia Matki Polki - Lodz
  • Institutul Oncologic "Prof. Dr. Ion Chiricuta" - Cluj-Napoca
  • Centrul de Oncologie SF Nectarie SRL - Craiova
  • Hospital Universitari Dexeus - Barcelona
  • Hospital Universitari Vall D´Hebron - Barcelona
  • Institut Català d'Oncologia Hospital Duran i Reynals - Barcelona
  • Hospital Puerta de Hierro - Majadahonda

California

  • University of California Los Angeles - Los Angeles

Colorado

  • Sarah Cannon Research Institute - Denver

Minnesota

  • HealthPartners Institute - Regions Cancer Care Center, - Saint Paul

Oklahoma

  • Oklahoma University , Stephenson Cancer Center - Oklahoma City

Texas

  • NEXT Oncology - San Antonio

Trial Details

FieldValue
Enrollment Target 197 participants
Start Date 2020-06-29
Est. Completion 2027-11
Phase Phase 1

Sponsor

BioInvent International AB

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04219254

The ClinicalTrials.gov registry entry for NCT04219254 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The listed sponsor is BioInvent International AB, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which BI1206 is the first listed.

NCT04219254 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT04219254 about?

NCT04219254 is a clinical study titled "A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

What is the current status of trial NCT04219254?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 197 participants. The study started on 2020-06-29. Estimated completion is 2027-11.

What conditions does trial NCT04219254 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT04219254?

The interventions under investigation include: BI1206 (DRUG).

Who is sponsoring clinical trial NCT04219254?

This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04219254 being conducted?

This trial has 20 study locations across California, Colorado, Minnesota, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.